Search the Newsreel

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Twist Bioscience (NASDAQ:TWST) Trading Down 4.3% - Here's What Happened

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

Artisan Partners group (TWST) discloses 4.8M-share position in Twist Bioscience

Artisan Partners Asset Management Inc. and its affiliates have disclosed a beneficial ownership of 4,802,017 common shares, representing a 7.7% stake, in Twist Bioscience Corporation (TWST). This position is held on behalf of Artisan Partners Limited Partnership's discretionary clients, with shared voting power over …

Twist Bioscience stock hits 52-week high at 126.22 USD

Twist Bioscience stock reached a new 52-week high of $126.22, trading just 1% below this peak and marking a remarkable 440% surge from its 52-week low. The company also reported strong fiscal third-quarter 2026 revenues of $118.4 million, exceeding Wall Street estimates, although adjusted …

Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock

Twist Bioscience CEO Emily Leproust sold 113,318 shares of company stock for over $14.18 million, reducing her ownership by 12.16%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, with the stock trading near its one-year high. Despite missing EPS estimates, analysts …

Twist Bioscience CEO Emily Leproust Executes Stock Option Exercise and Sells 113,318 Shares Under 10b5-1 Plan

Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), exercised stock options for 113,318 shares and subsequently sold them for a weighted average price of $125.1615 per share on August 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan established in …

Twist Bioscience (TWST) insider Leproust plans resale after option exercise

Twist Bioscience insider Emily M. Leproust has filed to resell up to 19,952 shares of common stock, valued at over $2.49 million, following a stock option exercise on August 12, 2026. This transaction is detailed in a Form 144 SEC filing, which also indicates …

E. Ohman J or Asset Management AB Makes New Investment in Twist Bioscience Corporation $TWST

E. Ohman J or Asset Management AB has initiated a new position in Twist Bioscience Corporation, acquiring 8,287 shares valued at approximately $853,000. This investment comes as other major institutional investors, such as ARK Investment Management and Millennium Management, have also increased their holdings …

Twist Bioscience (TWST) stake of 3.5% reported by William Blair Investment Management

William Blair Investment Management, LLC has reported a 3.5% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,174,594 shares. This filing, a Schedule 13G/A, indicates that the investment firm has sole voting power over 1,975,454 shares and sole dispositive power over all 2,174,594 …

Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High - Here's What Happened

Twist Bioscience (NASDAQ:TWST) reached a new 52-week high, trading as high as $121.50, despite its average analyst price target being below current trading levels. The company reported higher-than-expected revenue but a wider adjusted loss per share. While institutional investors have increased their holdings, company …

TWST shareholder (NASDAQ: TWST) files to sell 113,318 common shares

Emily M. Leproust, a shareholder of Twist Bioscience Corp (NASDAQ: TWST), has filed a Form 144 notice indicating her intent to sell 113,318 shares of common stock through Fidelity Brokerage Services LLC. The aggregate market value of this proposed sale is $14,183,056.89, with the …

Twist Bioscience TWST Jumps As Guidance, Targets And Cash Raise Align

Twist Bioscience (TWST) saw its stock jump after exceeding Q3 revenue expectations, raising its full-year 2026 guidance, and targeting adjusted EBITDA breakeven in Q4. Analyst firms like TD Cowen, Piper Sandler, and Baird increased their price targets to $115, citing strong demand from AI-enabled …

Twist Bioscience (TWST) Is Up 26.3% After Equity Raise And Guidance Hike Has The Bull Case Changed?

In early August 2026, Twist Bioscience completed a US$300 million follow-on common stock offering at US$96 per share after raising its fiscal 2026 revenue guidance to US$456 million–US$457 million and reporting third-quarter sales of US$118.38 million despite a net loss of US$35.05 million. Alongside …

Twist Bioscience (TWST) Is Up 26.3% After Capital Raise And Guidance Hike Amid Legal Settlement Talks - Has The Bull Case Changed?

In early August 2026, Twist Bioscience completed a US$300 million follow-on common stock offering at US$96 per share after raising its fiscal 2026 revenue guidance to US$456 million–US$457 million and reporting third-quarter sales of US$118.38 million despite a net loss of US$35.05 million. Alongside …

Twist Bioscience (TWST) Could Be 25% Overvalued Following Higher Revenue Guidance

Twist Bioscience Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:TWST) 2026-08-07

Twist Bioscience Corporation (NASDAQ: TWST) released its Q3 2026 earnings call presentation. The company reported an EPS of -$0.56, missing estimates by $0.38, while revenue reached $118.38M, surpassing expectations by $3.83M and representing a 23.24% year-over-year increase. This presentation was published in conjunction with …

Revenue Growth Reinforces Twist Bioscience Corp.’s (TWST) Technology Leadership

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104

Analysts have increased their price target for Twist Bioscience Corporation (NASDAQ:TWST) to US$104 after the company's Q3 results showed revenue exceeding expectations, despite a statutory loss. The upgraded target reflects an improved revenue outlook, with forecasts predicting significant growth in 2027, even though the …

Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has received a "Moderate Buy" consensus recommendation from brokerages, with eight buy ratings, one hold, and one sell among ten analysts. Despite an average 12-month price target of $98.30, below its recent opening price of $115.01, the company reported strong …

FMR LLC discloses 7.6% Twist Bioscience (TWST) holding in new ownership filing

FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 7.6% in Twist Bioscience Corp (TWST) as of June 30, 2026. This translates to 4,703,044.11 shares, with FMR LLC holding sole dispositive power over all these shares and sole voting power over …

Twist Bioscience Nets ~$327 Million From $96-Per-Share Underwritten Stock Offering

Twist Bioscience has successfully completed an underwritten stock offering, selling 3,125,000 shares of common stock at $96.00 per share, with the underwriters fully exercising their option for an additional 468,750 shares. This offering is expected to generate approximately $327.1 million in net proceeds after …

Twist Bioscience (TWST) Jumps As Guidance, Offering Reset The Trade

Twist Bioscience (TWST) saw its stock jump over 16% after reporting strong Q3 revenue, exceeding consensus, and raising its Q4 and FY26 revenue guidance. The company also announced an upsized $300M stock offering to fund R&D and manufacturing expansion, which, despite dilution, is seen …

Twist Bioscience (NASDAQ: TWST) COO sells 2,888 shares for tax withholding

Patrick John Finn, President and COO of Twist Bioscience (NASDAQ: TWST), sold 2,888 shares of common stock on August 3, 2026, at an average price of $85.3212 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations related to …

Twist Bioscience TWST Rallies As Guidance And Capital Raise Reset The Bar

Twist Bioscience (TWST) experienced a significant stock rally of 16.14% following positive Q3 results, robust Q4 and FY26 guidance, and a $300M equity offering. The company beat revenue expectations, increased its full-year guidance, and is targeting adjusted EBITDA breakeven, signaling an improved path towards …

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety (NASDAQ:TWST)

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

(RTTNews) - Twist Bioscience Corporation (TWST), a mid-cap growth biotechnology company, announced the pricing of an underwritten public offering of $250 million worth of shares of its common stock. The company priced 3.12 million shares at $96.00 per share. Twist also granted underwriters a …

Twist Bioscience (TWST) Jumps As Revenue, Targets And Offering Reshape The Trade

Twist Bioscience (TWST) Stock Rally Faces Pressure From Fresh Losses

Twist Bioscience prices $300M stock offering at $96 per share

Twist Bioscience Corporation announced it has priced an underwritten public offering of 3,125,000 shares of common stock at $96.00 per share, aiming to raise $300.0 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase additional shares. The net …

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Corporation announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at $96.00 per share, aiming to raise $300.0 million. The company plans to use the net proceeds for research and development investments, expanding manufacturing capacity …

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 4, 2026

Twist Bioscience Corporation announced that it will grant a total of 44,434 restricted stock units (RSUs) to 24 recently hired individuals as an inducement for their employment. These grants are made under Twist's Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq …

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation announced a proposed underwritten public offering of $250.0 million of its common stock, with an option for underwriters to purchase an additional $37.5 million. The company plans to use the net proceeds, along with existing cash, for research and development investments, …